Impact on estrogen receptor binding and target tissue uptake of [ 18F]fluorine substitution at the 16α-position of fulvestrant (Faslodex; ICI 182,780)

Nuclear Medicine and Biology

Volumn 31, Issue 6, 2004, Pages 691-698

  Seimbille, Yann ^a   Bénard, François ^a   Rousseau, Jacques ^a   Pepin, Emilie ^a   Aliaga, Antonio ^a   Tessier, Guillaume ^a   Van Lier, Johan E ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Antiestrogen therapy; Breast cancer; Estrogen receptor; Fluor 18; PET; Positron emission tomography; Radiopharmaceutical

Indexed keywords

ESTROGEN RECEPTOR; FLUORINE 18; FULVESTRANT;

ALPHA CHAIN; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG HYDROLYSIS; DRUG LABELING; DRUG RECEPTOR BINDING; FEMALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; RAT; STEREOCHEMISTRY;

ANIMALS; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; FLUORINE RADIOISOTOPES; INDICATORS AND REAGENTS; ISOTOPE LABELING; MAMMARY NEOPLASMS, EXPERIMENTAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; SULFATES; TISSUE DISTRIBUTION; UTERUS;

EID: 3042753367     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2004.02.010     Document Type: Article

References (40)

1. McGuire W.L. Hormone receptors Their role in predicting prognosis and response to endocrine therapy. Semin Oncol. 5:1978;428-433
2. Hulka B.S. Epidemiology of susceptibility to breast cancer. Prog Clin Biol Res. 395:1996;289-295
3. Fuqua S.A., Fitzgerald S.D., Allred D.C., Elledge R.M., Nawaz Z., McDonnell D.P., O'Malley B.W., Greene G.L., McGuire W.L. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 52:1992;483-486
4. Johnston S.R. Systemic treatment of metastatic breast cancer. Hosp Med. 62:2001;289-295
5. Vogel C.L. Update on the current use of hormonals as therapy in advanced breast cancer. Anticancer Drugs. 14:2003;265-273
6. Buzdar A.U. Tamoxifen's clinical applications old and new. Arch Family Med. 9:2000;906-912
7. Buzdar A.U. Endocrine therapy in the treatment of metastatic breast cancer. Sem Oncol. 28:2001;291-304
8. Santen R.J., Manni A., Harvey H., Redmond C. Endocrine treatment of breast cancer in women. Endocrine Rev. 11:1990;221-265
9. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 86:1994;527-537
10. Wolf D.M., Jordan V.C., William L. Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Res Treat. 27:1993;27-40
11. Jordan V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem. 46:2003;883-908
12. Jordan V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem. 46:2003;1081-1111
13. Brueggemeier R.W. Aromatase, aromatase inhibitors, and breast cancer. Am J Therapeutics. 8:2001;333-344
14. Miller W.R., Dixon J.M. Antiaromatase agents Preclinical data and neoadjuvant therapy. Clin. Breast Cancer. 1:2000;S9-14
15. Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51:1991;3867-3873
16. Coopman P., Garcia M., Brünner N., Derocq D., Clarke R., Rochefort H. Anti-proliferative and antiestrogenic effects of ICI 164, 384 and ICI 182, 780 in 4-OH-tamoxifen resistant human breast-cancer cells. Int J Cancer. 56:1994;295-300
17. Jones S.E. A new estrogen receptor antagonist - an overview of available data. Breast Cancer Res Treat. 75:2002;S19-21
18. Morris C., Wakeling A.E. Fulvestrant (′Faslodex') - a new treatment option for patients progressing on prior endocrine therapy. Endocrine-Related Cancer. 9:2002;267-276
19. Bross P.F., Cohen M.H., Williams G.A., Pazdur R. FDA drug approval summaries Fulvestrant. The Oncologist. 7:2002;477-480
20. Fawell S.E., White R., Hoare S., Sydenham M., Page M., Parker M.G. Inhibition of estrogen receptor-DNA binding by the 'pure' antiestrogen ICI 164, 384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA. 87:1990;6883-6887
21. Dauvois S., Daniellan P.S., White R., Parker M.G. Antiestrogen ICI 164, 384 reduces cellular estrogen content by increasing its turnover. Proc Natl Acad Sci USA. 89:1992;4037-4041
22. Dauvois S., White R., Parker M.G. The antiestrogen ICI 182, 780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 106:1993;1377-1388
23. Parker M.G. Action of pure antiestrogens in inhibiting estrogen receptor function. Breast Cancer Res Treat. 26:1993;131-137
24. Wakeling A.E., Slater S.R. Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites. Cancer Treat Rep. 64:1980;741-744
25. DaSilva J.N., Crouzel C., van Lier J.E. Synthesis of nca 7α-(11-[18F]fluoroundecyl)-estradiol Evaluation of a vector for estrogen receptor based agents. J Label Compd Radiopharm. 26:1989;342S-343S
26. DaSilva J.N., van Lier J.E. Synthesis and structure-affinity of a series of 7α-undecylestradiol derivatives A potential vector for therapy and imaging of estrogen receptor-positive cancers. J Med Chem. 33:1990;430-434
27. 125I]iodophenoxy)undecyl]-17β-estradiol A potent vector for therapy of adrenal and estrogen receptor-positive cancers. J Steroid Biochem Mol Biol. 37:1990;77-83
28. Kiesewetter D.O., Katzenellenbogen J.A., Kilbourn M.R., Welch M.J. Synthesis of 16-fluoroestrogens by unusually facile fluoride ion displacement reactions Prospects for the preparation of fluorine-18 labeled estrogens. J. Org. Chem. 49:1984;4900-4905
29. Kiesewetter D.O., Kilbourn M.R., Landvatter S.W., Heiman D.F., Katzenellenbogen J.S., Welch M.J. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 25:1984;1212-1221
30. Lim J.L., Berridge M.S., Tewson T.J. Preparation of [18F]16α- fluoro-17β-estradiol by selective nucleophilic substitution. J Label Compd Radiopharm. 35:1994;176-177
31. Lim J.L., Zheng L., Berridge M.S., Tewson T.J. The use of 3-methoxymethyl-16β, 17β-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16α-fluoroestradiol. Nucl Med Biol. 23:1996;911-915
32. Seimbille Y., Bénard F., van Lier J.E. Synthesis of 16α-fluoro ICI 182, 780 derivatives Powerful antiestrogens to image estrogen receptor densities in breast cancer by positron emission tomography. J Chem Soc Perkin Trans 1. 20:2000;2275-2281
33. 18F] difluoroestradiols and their 11β-methoxy derivatives for estrogen receptor imaging. J Label Compd Radiopharm. 44:2001;S348-350
34. 18F labeled difluoroestradiols Preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids. 67:2002;765-775
35. Berridge M.S., Franceschini M.P., Rosenfeld E., Tewson T.J. Cyclic sulfates Useful substrates for selective nucleophilic substitution. J Org Chem. 55:1990;1211-1217
36. 18F]fluoroestradiol. Appl. Radiat. Isot. 47:1996;395-399
37. Levesque C., Merand Y., Dufour J.-M., Labrie C., Labrie F. Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem. 34:1991;1624-1630
38. Parisot J.P., Hu X.F., Sutherland R.L., Wakeling W., Zalcberg J.R., DeLuise M. The pure antiestrogen ICI 182, 780 binds to a high-affinity site distinct from the estrogen receptor. Int J Cancer. 62:1995;480-484
39. Dudley M.W., Sheeler C.Q., Wang H., Khan S. Activation of the human estrogen receptor by the antiestrogen ICI 182, 780 and tamoxifen in yeast genetic systems Implications for their mechanism of action. Proc Natl Acad Sci USA. 97:2000;3696-3701
40. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:1997;753-758